Open Access Green as soon as Postprint is submitted to ZB.
CNS-targeting pharmacological interventions for the metabolic syndrome.
J. Clin. Invest. 130, 4058-4071 (2019)
Research data DOI Order publishers version
The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Glucagon-like Peptide-1; Controlled-release Phentermine/topiramate; Dependent Insulinotropic Peptide; Cannabinoid-1 Receptor Blocker; Melanin-concentrating Hormone; Neurons Regulate Energy; Once-daily Liraglutide; Diet-induced Obesity; Food-intake; Weight-loss
ISSN (print) / ISBN 0021-9738
Quellenangaben Volume: 130, Issue: 10, Pages: 4058-4071
Publisher American Society of Clinical Investigation
Publishing Place 2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
Institute(s) Institute of Diabetes and Obesity (IDO)